<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968344</url>
  </required_header>
  <id_info>
    <org_study_id>09-121</org_study_id>
    <secondary_id>MA02001</secondary_id>
    <nct_id>NCT00968344</nct_id>
  </id_info>
  <brief_title>Muscle Mass During Space Exploration</brief_title>
  <official_title>An Integrated Low-Volume Nutritional Countermeasure to Maintain Muscle Mass and Function During Space Exploration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Space Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the following hypotheses:

        1. Bedrest will blunt the anabolic response to a mixed nutrient meal, facilitating a loss
           of muscle mass and functional capacity that is only partially restored during
           rehabilitation.

        2. Enriching daily meals with leucine will promote protein synthesis and maintain the
           anabolic response to mixed nutrient meal ingestion. This will preserve lean muscle mass
           and function during bedrest and facilitate the recovery of functional and metabolic
           capacity during rehabilitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our long-term goal is to identify, prevent and remedy defects in the metabolic pathway that
      contribute to the loss of muscle mass and function during exposure to microgravity.
      Demographic data indicate that the average age of shuttle crew members has increased from
      40.7 yrs in 1995 to 46.7 yrs in 2007 with an increasing number of astronauts over 50 yrs of
      age. We contend that the loss of muscle mass and function during spaceflight is facilitated
      by an age-associated, progressive impairment in the ability to mount an anabolic response to
      standard mixed nutrient meals. We propose that enriching daily meals with a low-volume
      leucine supplement will reduce the deleterious effects of microgravity on skeletal muscle and
      facilitate recovery during rehabilitation.

      We will employ our established 14 day bed rest protocol to model the skeletal muscle
      unloading that occurs during microgravity. We will also examine recovery of muscle mass and
      functional capacity during a 7 day rehabilitation period. We will study 2 groups: CON
      (Bedrest/Recovery + Placebo; n=15), LEU (Bedrest/Recovery + Leucine; n=15). We will assess a)
      markers of translation initiation, b) muscle protein synthesis, c) muscle mass and body
      composition and d) strength and aerobic capacity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention: leucine</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lean Leg Mass</measure>
    <time_frame>At baseline prior to beginning bed rest and after 14 days of bed rest</time_frame>
    <description>DEXA scan of both legs pre/post bed rest</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>Leucine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-4 g Leucine added to daily meals during bed rest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3-4 g Alanine added to daily meals during bed rest</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Leucine</intervention_name>
    <description>3-4g Leucine added to daily meals</description>
    <arm_group_label>Leucine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alanine</intervention_name>
    <description>Powered amino acid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 45-60

          2. Ability to sign informed consent

        Exclusion Criteria:

          1. Subjects with cardiac abnormalities considered exclusionary by the study physicians

          2. Subjects with uncontrolled metabolic disease

          3. A GFR &lt;65 mL/min/1.73m2 or evidence of kidney disease or failure

          4. Subjects with vascular disease or risk factors of peripheral atherosclerosis

          5. Any history of hypo- or hyper-coagulation disorders. (e.g., Coumadin use or history of
             DVT or PE)

          6. Subjects with chronically elevated systolic pressure &gt;150 or a diastolic blood
             pressure &gt; 100

          7. Subjects with implanted electronic devices (e.g., pacemakers, electronic infusion
             pumps, stimulators)

          8. Subjects with recently (6 months) treated cancer other than basal cell carcinoma

          9. Any subject currently on a weight-loss diet or a body mass index &gt; 30 kg/m2

         10. Inability to abstain from smoking for duration of study

         11. A history of &gt; 20 pack per year smoking

         12. Any subject that is HIV-seropositive or has active hepatitis

         13. Recent anabolic or corticosteroids use (within 3 months)

         14. Subjects with hemoglobin or hematocrit lower than accepted lab values

         15. Agitation/aggression disorder

         16. History of stroke with motor disability

         17. A recent history (&lt;12 months) of GI bleed

         18. Any other condition or event considered exclusionary by the PI and faculty physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Paddon-Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Medical Branch at Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>August 28, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <results_first_submitted>December 1, 2017</results_first_submitted>
  <results_first_submitted_qc>February 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2009-2014: we recruited and studied middle-aged men and women (45-60 years), representative of the ethnic makeup of the United States. Volunteers were recreationally active but athletically untrained.After providing written informed consent, volunteers were screened in the UTMB Institute for Translational Sciences–Clinical Research Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Leucine</title>
          <description>3-4 g Leucine added to daily meals during bed rest
Leucine: crystalline amino acid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>3-4 g Alanine added to daily meals during bed rest
Alanine: crystalline amino acid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">Includes screen fails</participants>
                <participants group_id="P2" count="20">Includes screen fails</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy community-dwelling men and women aged 45–60 y old participated in this randomized, double-blind, placebo controlled study. Volunteers were recreationally active but athletically untrained.</population>
      <group_list>
        <group group_id="B1">
          <title>Leucine</title>
          <description>3-4 g Leucine added to daily meals during bed rest
Leucine: 3-4g Leucine added to daily meals</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>3-4 g Alanine added to daily meals during bed rest
Alanine: Powered amino acid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Screen fails not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lean Leg Mass</title>
        <description>DEXA scan of both legs pre/post bed rest</description>
        <time_frame>At baseline prior to beginning bed rest and after 14 days of bed rest</time_frame>
        <population>Healthy community-dwelling men and women aged 45–60 y</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Subjects in the control group consumed a 3-4 g of alanine at each meal (an isonitrogenous control)</description>
          </group>
          <group group_id="O2">
            <title>Leucine (Intervention) Group</title>
            <description>Subjects in the leucine group consumed 3-4 g of leucine at each meal during bed rest.</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Leg Mass</title>
          <description>DEXA scan of both legs pre/post bed rest</description>
          <population>Healthy community-dwelling men and women aged 45–60 y</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.2"/>
                    <measurement group_id="O2" value="-0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Leucine</title>
          <description>Leucine: 3-4g Leucine added to daily meals</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Alanine: Powered amino acid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Douglas Paddon-Jones, Professor</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-772-3073</phone>
      <email>djpaddon@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

